In this issue of JAMA Dermatology, Margolis et al 1 report the association of a thymic stromal lymphopoietin (TSLP) variant with disease remission in children with atopic dermatitis (AD), particularly in those carrying filaggrin gene (FLG) mutations. Thymic stromal lymphopoietin, an epithelial cell-derived cytokine, is a master initiator of helper T cell type 2 (T H 2) differentiation and allergic manifestations. 2 These results suggest that TSLP could be a possible dual factor in AD, capable of modulating the effects of FLG mutations in triggering allergic manifestations. Alternatively, this single-nucleotide polymorphism (SNP) variant could be in linkage disequilibrium, with a causative variant to be identified, localized within or outside TSLP. Functional and expression studies of this TSLP SNP variant will be instrumental to assess its role(s) in the disease.Atopic dermatitis is a relapsing chronic inflammatory skin disease characterized by eczematous skin lesions and intense pruritus 3 and is the most common inflammatory skin disorder, with an increasing prevalence. It affects up to 20% of children and 3% of adults in developed countries. Atopic dermatitis is an allergic disorder, often associated with asthma or other allergic manifestations. The cutaneous manifestations of atopy often represent the beginning of the atopic march. There is considerable clinical heterogeneity of the disease with regard to the age of onset, clinical manifestations, severity, and associated allergic manifestations and complications, suggesting etiological heterogeneity. Atopic dermatitis currently lacks specific effective treatment, although the use of calcineurin inhibitors has significantly brought a clinical benefit to patients.Atopic dermatitis is a multifactorial disease caused by complex interactions between multiple genetic determinants and environmental factors. A major breakthrough in the understanding of AD pathogenesis was the identification of mutations in FLG. 4 Loss-of-function mutations in FLG, encoding a key protein involved in maintaining skin barrier function, have been consistently, widely, and strongly associated with AD, demonstrating the important role of epidermal barrier defects in AD. To date, 4 recurrent FLG mutations (R501X, 2282del4, S3247X, and R2447X), with an estimated combined allele frequency of approximately 7% to 10%, and several less common variants have been identified in individuals of European descent. Notably, the same FLG mutations identified in the European population were rarely found in Asians ARTICLE INFORMATION 4. Brown SJ, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012; 132(3, pt 2):751-762. 5. Wang WL, Li HY, Zhang MS, et al. Thymic stromal lymphopoietin: a promising therapeutic target for allergic diseases. Int Arch Allergy Immunol. 2013;160(1):18-26. 6. Gao PS, Rafaels NM, Mu D, et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum.